The Glasgow prognostic score is valuable for colorectal cancer with both synchronous and metachronous unresectable liver metastases

Oncology Letters

Volumn 4, Issue 2, 2012, Pages 324-328

  Furukawa, Kenei ^a   Shiba, Hiroaki ^a   Haruki, Koichiro ^a   Fujiwara, Yuki ^a   Iida, Tomonori ^a   Mitsuyama, Yoshinobu ^a   Ogawa, Masaichi ^a   Ishida, Yuichi ^a   Misawa, Takeyuki ^a   Yanaga, Katsuhiko ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Colorectal cancer; Glasgow prognostic score; Liver metastasis; Prognosis

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CANCER DIAGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EVALUATION; COLORECTAL CANCER; FEMALE; GLASGOW PROGNOSTIC SCORE; HUMAN; INFLAMMATION; LIVER METASTASIS; MALE; PROGNOSIS; SCORING SYSTEM;

EID: 84861978377     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.722     Document Type: Article

References (30)

1. Weitz J, Koch M, Debus J, Höhler T, Galle PR and Büchler MW: Colorectal cancer. Lancet 365: 153-165, 2005.
2. O'Reilly DA and Poston GJ: Colorectal liver metastases: current and future perspectives. Future Oncol 2: 525-531, 2006.
3. Rodgers MS and McCall JL: Surgery for colorectal liver metastases with hepatic lymph node involvement: a systematic review. Br J Surg 87: 1142-1155, 2000.
4. Martin LW and Warren RS: Current management of colorectal liver metastases. Surg Oncol Clin North Am 9: 853-876, 2000.
5. Penna C and Nordlinger B: Colorectal metastasis (liver and lung). Surg Clin North Am 82: 1075-1090, 2002.
6. Kato T, Yasui K, Hirai T, Kanemitsu Y, Mori T, Sugihara K, Mochizuki H and Yamamoto J: Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763cases recorded at 18institutions. Dis Colon Rectum 46: S22-S31, 2003.
7. Nordlinger B, Guiguet M, Vaillant JC, Balladur P, BoudjemaK, Bachellier P and Jaeck D: Surgical resection of colorectal carcinoma metastases to the liver: a prognostic scoring system to improve case selection, based on 1568patients. Cancer 77: 1254-1262, 1996.
8. Seifert JK, Böttger TC, Weigel TF, Gönner U and JungingerT: Prognostic factors following liver resection for hepatic metastases from colorectal cancer. Hepatogastroenterology 47: 239-246, 2000.
9. Fong Y, Fortner J, Sun RL, Brennan MF and Blumgart LH: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001consecutive cases. Ann Surg 230: 309-321, 1999.
10. Minagawa M, Makuuchi M, Torzilli G, Takayama T, Kawasaki S, Kosuge T, Yamamoto J and Imamura H: Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Ann Surg 231: 487-499, 2000.
11. Jonas S, Thelen A, Benckert C, Spinelli A, Sammain S, NeumannU, Rudolph B and Neuhaus P: Extended resections of liver metastases from colorectal cancer. World J Surg 31: 511-521, 2007.
12. Jaeck D, Oussoultzoglou E, Rosso E, Greget M, Weber JC and Bachellier P: A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases. Ann Surg 240: 1037-1049, 2004.
13. Wood CB, Gillis CR and Blumgart LH: A retrospective study of the natural history of patients with liver metastases from colorectal cancer. Clin Oncol 2: 285-288, 1976.
14. Wagner JS, Adson MA, Van Heerden JA, Adson MH and IlstrupDM: The natural history of hepatic metastases from colorectal cancer: a comparison with resective treatment. Ann Surg 199: 502-508, 1984.
15. McMillan DC: An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc 67: 257-262, 2008.
16. McMillan DC, Crozier JE, Canna K, Angerson WJ and McArdleCS: Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis 22: 881-886, 2007.
17. Japanese Society for Cancer of the Colon and Rectum: Japanese classification of colorectal carcinoma. 1st English ed. Kanehara Co., Ltd., Tokyo, 1997.
18. Sobin LH and Wittekind (eds). UICC TNM classification of malignant tumors. 5th edition. John Wiley & Sons, Inc., New York, 1997.
19. Jaeck D, Bachellier P, Guiguet M, Boudjema K, Vaillant JC, Balladur P and Nordlinger B: Long-term survival following resection of colorectal hepatic metastases. Association Française de Chirurgie. Br J Surg 84: 977-980, 1997.
20. Forrest LM, McMillan DC, McArdle CS, Angerson WJ and Dunlop DJ: Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 89: 1028-1030, 2003.
21. Forrest LM, McMillan DC, McArdle CS, Angerson WJ and Dunlop DJ: Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer 90: 1704-1706, 2004.
22. Al Murri AM, Bartlett JM, Canney PA, Doughty JC, Wilson C and McMillan DC: Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer 94: 227-230, 2006.
23. Crumley AB, McMillan DC, McKernan M, McDonald AC and Stuart RC: Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer. Br J Cancer 94: 637-641, 2006.
24. Glen P, Jamieson NB, McMillan DC, Carter R, Imrie CW and McKay CJ: Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer. Pancreatology 6: 450-453, 2006.
25. Ramsey S, Lamb GW, Aitchison M, Graham J and McMillanDC: Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. Cancer 109: 205-212, 2007.
26. Leitch EF, Chakrabarti M, Crozier JE, McKee RF, Anderson JH, Horgan PG and McMillan DC: Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br J Cancer 97: 1266-1270, 2007.
27. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL and Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med343: 905-914, 2000.
28. Douillard JY, Cunningham D, Roth AD, Navarro M, JamesRD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355: 1041-1047, 2000.
29. De Gramont A, Vignoud J, Tournigand C, Louvet C, AndréT, Varette C, Raymond E, Moreau S, Le Bail N and Krulik M: Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 33: 214-219, 1997.
30. Poston GJ: The use of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer. Eur J Surg Oncol 31: 325-330, 2005.